Blog
RSS FeedPosted by Michael Wonder on 21 May 2020
Proposal to award sole supply of infliximab in DHB hospitals
21 May 2020 - PHARMAC is proposing to award sole supply of infliximab, a biologic medicine used to treat a ...
Posted by Michael Wonder on 20 Apr 2020
Modifying funded access to mifepristone and misoprostol
20 April 2020 - PHARMAC is seeking feedback on a proposal to change funded access arrangements to two medicines currently ...
Posted by Michael Wonder on 02 Apr 2020
Proposal to fund modified release pancreatic enzyme granules (Creon Micro)
2 April 2020 - PHARMAC is seeking feedback on a proposal to fund a new modified-release granule formulation of pancreatic ...
Posted by Michael Wonder on 24 Jan 2020
PHARMAC seeking views on new cystic fibrosis medicine
24 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) ...
Posted by Michael Wonder on 20 Jan 2020
Fees and charges proposal 2020-21
20 January 2020 - The TGA is undertaking a consultation through its website to seek stakeholder's views on TGA’s proposed fees ...
Posted by Michael Wonder on 15 Jan 2020
Proposal to fund betamethasone dipropionate with calcipotriol (Enstilar) foam spray for psoriasis
15 January 2020 - PHARMAC is seeking feedback on a proposal to fund a new topical psoriasis medicine, betamethasone dipropionate ...
Posted by Michael Wonder on 14 Jan 2020
It's given me so much hope': PHARMAC announces breast cancer drug deal
15 January 2020 - Wiki Mulholland has watched friends die around her since her terminal breast cancer diagnosis 18 months ...
Posted by Michael Wonder on 14 Jan 2020
PHARMAC seeking views on new breast cancer medicine
15 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) ...
Posted by Michael Wonder on 18 Dec 2019
Funding of vitamin A oral liquid
18 December 2019 - PHARMAC is pleased to announce that PHARMAC has approved the use of the Exceptional Circumstances framework ...
Posted by Michael Wonder on 18 Dec 2019
Proposal to fund mepolizumab for the treatment of severe refractory eosinophilic asthma
18 December 2019 - PHARMAC is seeking feedback on a proposal to fund mepolizumab (Nucala), a new treatment for severe ...
Posted by Michael Wonder on 16 Dec 2019
Proposal to widen funded access to lenalidomide for multiple myeloma
16 December 2019 - PHARMAC is seeking feedback on a proposal to widened funded access to lenalidomide (Revlimid) to include ...
Posted by Michael Wonder on 09 Dec 2019
Proposals for funding in the blood, alimentary and immunosuppressant therapy areas
9 December 2019 - PHARMAC is seeking feedback on proposals to widen funded access to medicines in the blood, alimentary ...
Posted by Michael Wonder on 31 Oct 2019
Proposal to widen access to rituximab and change the funded brand for all funded indications excluding rheumatoid arthritis
31 October 2019 - PHARMAC is seeking feedback on a proposal to make changes to the funded brand of rituximab, ...
Posted by Michael Wonder on 22 Oct 2019
Proposal to widen access to bortezomib for multiple myeloma and amyloidosis
22 October 2019 - PHARMAC is seeking feedback on the proposal to change the Special Authority criteria for bortezomib. ...
Posted by Michael Wonder on 07 Aug 2019
Proposal for funding of oncology, multiple sclerosis and respiratory treatments
7 August 2019 - PHARMAC is seeking feedback on a proposal to fund three new treatments and widen access to ...